Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080780 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects
A Phase 1 study of CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction], sponsored by Ventrus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02080780 is a Phase 1 study of CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction] that has completed, run by Ventrus Biosciences. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02080780, a Phase 1 study of CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction], has completed, sponsored by Ventrus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the drug-drug interaction potential of clarithromycin XL on Diltiazem hydrochloride (DTZ) 2% cream.
Conditions Studied
Interventions
- DRUG Clarithromycin XL
- DRUG 2% Diltiazem
Study Locations (1)
New Jersey
- TKL Research - Paramus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02080780
The ClinicalTrials.gov registry entry for NCT02080780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ventrus Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction] appearing as the primary indexed condition, and to 2 interventions - of which Clarithromycin XL is the first listed.
NCT02080780 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02080780 about?
NCT02080780 is a clinical study titled "Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects". The purpose of this study is to evaluate the drug-drug interaction potential of clarithromycin XL on Diltiazem hydrochloride (DTZ) 2% cream.
What is the current status of trial NCT02080780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-09. Estimated completion is 2013-10.
What conditions does trial NCT02080780 study?
This clinical trial studies the following conditions: CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction].
What interventions are being tested in trial NCT02080780?
The interventions under investigation include: Clarithromycin XL (DRUG), 2% Diltiazem (DRUG).
Who is sponsoring clinical trial NCT02080780?
This trial is sponsored by Ventrus Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02080780 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.